Related topics: Materials & Formulation
Baxter has said its Vero cell production technology has made it possible to complete production of its first commercial batches of H1N1 vaccine 12 weeks after receiving the virus strain.
The company believes the speed of this turnaround represents an innovation in vaccine production and is a validation of its proprietary technology.
Baxter is now in discussing distribution plans with health authorities and is also ensuring that the company is in accordance with requirements needed to support marketing approval.
Clinical trials to evaluate the safety of the mock-up vaccine in adults, the elderly and children will begin this month.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
